Business
Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit
Highlights: Strategic Validation: Industry feedback confirms Rakovina’s approach tar...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit\nHighlights: Strategic Validation: Industry feedback confirms Rakovina’s approach targeting PTEN-deficient tumours with brain-penetrant ATR/mTOR inhibitors addresses critical gaps left by recent late-stage clinical setbacks in the field.Expanded Opportunity: Discussions with major pharmaceutical partners highlight emerging demand for novel antibody-drug conjugate (ADC) payloads, validating the potential of Rakovina’s kt-3000 series. VANCOUVER, British Columbia, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0)(“Rakovina” or the “Company”), a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today provided a corporate update following the participation of its President and Chief Scientific Officer, Prof. Mads Daugaard, at the 9th Annual DNA Damage Response (DDR) Inhibitors Summit in Boston, MA. The summit, which gathered global academic and industry leaders from institutions including Dana-Farber, MD Anderson, Merck, and Roche, served as a critical forum for discussing the future of DDR therapeutics. Prof. Daugaard presented Rakovina’s AI-driven strategy to develop brain-penetrant inhibitors and participated in expert panels on translational strategy and investment alignment. Validating the Strategy: Solving the \"Brain Penetration\" Gap A focal point of the summit was the clinical landscape of ATR inhibitors, specifically considering recent Phase 3 data in non-small cell lung cancer (NSCLC) Rakovina’s presentation highlighted a distinct competitive advantage: unlike current clinical-stage candidates, Rakovina’s lead kt-5000 series is designed to be dual-targeting (ATR + mTOR) and brain-penetrant. “The consensus from the summit is that the field is hungry for a brain-penetrant ATR inhibitor,” said Prof. Mads Daugaard, Chief Scientific Officer of Rakovina Therapeutics. “While other programs face challenges with patient stratification and blood-brain barrier penetration, our data supports a different path: positioning ATR inhibition in a PTEN-deficient context with added mTOR blockade to shut down resistance pathways. The feedback we received from cli...